NEW YORK (GenomeWeb) – Sequenom said this week that its wholly owned subsidiary Sequenom Laboratories signed a national agreement with an unnamed insurance company for coverage of the MaterniT21 Plus non-invasive prenatal test. It is the third national coverage deal signed by Sequenom for the test. The insurer covers 13 million lives in the US and brings the total number of covered lives under agreement by the laboratory's diagnostic services to more than 140 million lives, Sequenom said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.